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GLOSSARY 
BART Blood Conservation Using Anti-fibrinolytics in a Randomized Trial
BSV between-subject variability 
BW body weight 
CLR renal clearance 
CL12 or CL21 inter-compartmental clearances from central to peripheral 
compartments and from peripheral to central compartments, 
respectively 
CLCr creatinine clearance 
CRD chronic renal dysfunction  
CV coefficient of variation 
GFR glomerular filtration rate 
KDOQI Kidney Disease Outcome Quality Initiative 
MD  maintenance infusion dose  
OFV objective function value  
PK pharmacokinetics 
Q3 flow rate between central and extracorporeal compartments (the CPB 
pump circuit) 
Scr serum creatinine concentration 
TXA tranexamic acid         
V1, V2 and V3 volumes of distribution of the central, peripheral and extracorporeal 
compartments, respectively 
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ABSTRACT 
Tranexamic acid (TXA), an effective antifibrinolytic agent that is cleared by glomerular 
filtration, is widely used for cardiopulmonary bypass (CPB) surgery.  However, an effective 
dosing regimen has not been fully developed in patients with renal impairment. The aims of 
this study are to characterize the inter-patient variability associated with pharmacokinetic 
parameters and to recommend a new dosing adjustment, based on the BART dosing regimen 
for CPB patients with chronic renal dysfunction (CRD). Recently published data on CPB 
patients with normal renal function (n=15) were re-examined with a two-compartment model 
using the ADAPT5® and NONMEMVII® to identify covariates that explain inter-patient 
variability and ascertain whether sampling strategies might affect parameter estimation.  A 
series of simulations was performed to adjust the BART dosing regimen for CPB patients 
with renal impairment.  Based on the 2-compartmental model, the number of samples 
obtained after discontinuation of TXA infusion was found not to be critical in parameter 
estimation (P > .05). Both body weight and creatinine clearance were identified as significant 
covariates (P < .005). Simulations showed significantly higher than normal TXA 
concentrations in CRD patients who received the standard dosing regimen in the BART trial. 
Adjustment of the maintenance infusion rate based on the percent reduction in renal clearance 
resulted in predicted plasma TXA concentrations that were safe and therapeutic (~ 100 mg·L
-
1
).  Our proposed dosing regimen, with consideration of renal function, is able to maintain 
effective target plasma concentrations below those associated with toxicity for patients with 
renal failure for CPB. 
Key word: Tranexamic acid, cardiopulmonary bypass, pharmacokinetic or population 
modeling, dose optimization 
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INTRODUCTION 
Tranexamic acid (TXA) is an anti-fibrinolytic agent used widely to minimize blood loss and 
transfusion during cardiac surgery with use of cardiopulmonary bypass (CPB). This synthetic 
lysine derivative has class I recommendation as a blood conservation strategy for cardiac 
surgical patients [1]. Previous studies have reported that 100 mg·L
-1
 TXA in plasma is
sufficient to allow for a complete anti-fibrinolytic effect [2], and the value was adopted as the 
desired therapeutic concentration for high-risk cardiac surgery patients. The dosing strategy 
developed by Dowd and coworkers [3] (loading infusion of 120 mg·kg
-1
·h
-1
 for 15 min,
followed by 16 mg·kg
-1
·h
-1
 for 10 h) for TXA for cardiac surgery with use of
cardiopulmonary bypass among patients with normal renal function (see Appendix A) was 
adopted by the BART Trial (Blood Conservation Using Anti-fibrinolytics in a Randomized 
Trial) [4].  As a result, this strategy has become widely used despite the fact that the optimal 
dosing regimen for TXA continues to be debated.  This is particular true in regards to the 
reduction of the maintenance infusion duration [5]. 
The characteristic of cardiac surgical population is changing; there are more older patients 
with a greater burden of comorbid diseases, and typically patients undergo increasingly more 
complex and high-risk surgery with high blood transfusion requirements. More specifically, 
approximately 50% of our surgical population has chronic renal dysfunction (CRD) and 
incurs a high risk of postoperative morbidity and mortality [6].  This is of particular concern 
with respect to TXA, a drug that is primarily eliminated via glomerular filtration [7, 8]. There 
are considerable safety and cost implications for high TXA (60-260 mg·kg
-1
) doses that may
render patients susceptible to postoperative non-ischemic seizures, prolonging ICU and 
hospital stay [9-13]. Given this high risk patient population, there is no consensus on the 
optimal dosing regimen. 
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Our study has two specific aims.  First, we revisited some recently published data [5, 14] on 
cardiac surgical patients with normal renal function who were given the BART dose to 
identify important patient-specific covariates that may affect TXA disposition using a 
population pharmacokinetic modeling approach. Secondly, we utilized the model developed 
to explore an optimal dosing algorithm using a series of simulations of patients with various 
severity of CRD to determine if the proposed regimen can maintain stable TXA 
concentrations at the therapeutic target concentration (100 mg·L
-1
).
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METHODS 
Information on Patient Data for TXA Administration 
Published works of Wąsowicz [14] and Sharma [5] and coworkers consisted of 
concentration-time data on TXA for fifteen patients with normal renal function undergoing 
cardiac surgery with use of CPB.  Patient demographics and peri-operative variables are 
summarized in Supplemental Table 1. Within these studies, TXA was administered using a 
modified BART dosing regimen consisting of a 120 mg·kg
-1
·h
-1
 (30 mg·kg
-1
) loading dose
infused over 15 min followed by 16 mg·kg
-1
·h
-1 
maintenance infusion until chest closure
(~3.5 h), with an additional 2 mg·kg
-1
 bolus dose given within the CPB pump prime (~2 L).
The CPB flow was approximately 5 L·min
-1
.  Pharmacokinetic (PK) analysis was performed
after dividing the cardiac operation duration into 5 phases: for the loading infusion dose 
(Phase I), chest open (Phase II), CPB (Phase III), chest closure (Phase IV) and washout 
(Phase V); the maintenance infusion was given over Phases II to IV (see appendix A). 
Sampling was conducted over the five phases, with continued sampling during the washout 
period or Phase V after cessation of infusion. Similar schedules were found for both studies, 
with the exception that more samples were taken during Phase V for the Sharma study [5] (6-
8 samples) compared to Wąsowicz study (2 samples) [14]. Additionally, the maintenance 
infusion used by both studies was substantially shorter at 3.5 h compared to BART regimen 
at 10 h [3]. 
Modeling and Simulations 
Compartment model fitting to data. With the assumption that fluids in extracorporeal device 
(2L in volume) was not returned to patients at the end of surgery, a two compartment model 
was used to fit data for all phases simultaneously using ADAPT® (BMSR version 5, USC, 
Los Angeles, CA; see Appendix B for model and equations) to examine whether the number 
of samples obtained after discontinuation of TXA infusion is important for parameter 
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estimation. TXA was assumed to be 100% eliminated by kidney. The computational 
algorithm used was the maximum likelihood solution via the EM algorithm (MLEM), and the 
error variance function was defined as VARi = (σ1+σ2∙Y(θ,ti))
2, where σ1 is SDinter and σ2 is
SDslope. Differences in the estimates were compared using the Mann Whitney U test. 
Population modeling and covariates. Data from all 15 patients described by Sharma [5] and 
Wąsowicz and colleagues [14] were used for population analysis to identify important 
covariates that confer between- or inter-subject variability (BSV) and to estimate population 
parameters with NONMEMVII® (ICON Development Solution, version 7.2, Ellicott City, 
MD).  The algorithm used to arrive at the best model was via stochastic approximation EM 
(SAEM). Initially, a base population model was constructed without any covariates added 
(equations in Appendix B). As body weight and creatinine clearance are continuous variables, 
their effect on clearance (CL) or volume of distribution (V1) can be expressed in forms of 
linear, power and exponential functions in relation to their medians [15]. Improvement of fit 
was compared after adding each covariate combination to specific pharmacokinetic 
parameters and appraised with the use of objective function values (OFVs), which 
approximates -2 times the log-likelihood. The difference in -2 log likelihood across nested 
models approximates a Chi-square distribution. A stringent α-level (0.005) for significance 
was used to judge improvement to the model. The model with the greatest improvement of fit 
was selected to be the final model.  The internal validation techniques including basic 
goodness plots and visual predictive check plots were used to examine whether the final 
covariate model can adequately describe the data without bias. 
Simulations.  We conducted simulations using the 2-compartmental model to appraise the 
recent protocol of returning fluids in extracorporeal device to central compartment at end of 
CPB (Appendix B). We then simulated the impact of renal impairment upon plasma TXA 
concentrations when the BART dosing regimen was administered, or when 50 mg·kg
-1
 of
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TXA was infused over 15 min (200 mg·kg
-1
·h
-1
) among patients of varying severity of renal
dysfunction. This was achieved by setting the CLR (which equals GFR) as 100, 75, 50, 25, 10 
and 1% CLR (see supplemental Table 2) to denote varying degrees of renal insufficiency. 
According to the Kidney Disease Outcome Quality Initiative (KDOQI) clinical practice 
guideline [16, 17], the severity of chronic kidney disease can be categorized according to 
GFR (mL·min
-1
·1.73m
-2
) (Supplemental Table 2). These simulation parameters were utilized
to subsequently develop a dosing strategy for patients with renal failure. 
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 RESULTS 
Fitting. Our compartmental model fitted both sets of TXA data well, regardless of the 
number of samples [fewer [14] (Fig. 1A) or more [5] (Fig. 1B)] obtained after the infusion 
was stopped. The model demonstrated an accumulation of TXA in plasma during the first 5 
min (~ 170 mg·L
-1
), which remained at approximately 150 mg·L
-1
 during the chest opening
and CPB periods (Phases II and III). The model further showed that, upon termination of the 
maintenance infusion, TXA concentrations gradually decreased in a first-order manner over 
time (Fig. 1). Here, we found that the estimated parameters for renal clearance (CLR), central 
volume of distribution (V1), inter-compartmental clearances [CL12 = k12V1 (or CL21 = k21V2)] 
and peripheral volume of distribution (V2) were not significantly different between the two 
groups (P > .05; Table 1). However, parameters derived from the fit to the richer data set 
(Sharma and coworkers [5]) were associated with a smaller coefficient of variation (CVs) as 
the larger number of data points would reduce the uncertainty in parameters estimates (Fig. 1; 
Table 1).  We further performed simulations and found that the return of circuit fluids from 
the extracorporeal circuit after CPB did not perturb TXA kinetics (data not shown). 
Population and covariate model. Model testing, with incremental addition of covariates to 
the base model, led to the final model (I) that contained body weight and CLCr as covariates, 
and showed significantly reduced inter-patient variability in CLR (Δ=22.3%), V1 (Δ=19.9%), 
CL12 or CL21 (Δ=86.4%) and V2 (Δ=1.7%) (see Table 2 for detailed covariate model building 
steps). The CPB duration (τCPB) or infusion (τTXA) time were found not to be important (data 
no shown). Improvement of model fit in model I, with incorporation of covariate effects of 
body weight and CLcr on V1 and CLR, was seen when the regression line and the line of 
identity coalesce, and observations were similar to predictions (Fig. 2A). The population 
parameters estimated from final covariate model (model I) are summarized in Table 2. The 
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objective function value (OFV) revealed goodness of model fit, decreasing by 74 units (from 
591 to 517) with 3 degrees of freedom and reflecting a significant improvement based on the 
likelihood ratio test that corresponds to P < .005 (Table 2). Conditional weighted residuals 
were evenly distributed around zero and followed normal distribution, indicating reasonably 
reliable parameter estimation (Figs. 2B-D). The visual predictive check plot (replicate=100) 
showed the median and 95
th
  and 5
th
  percentiles of observed data lay within simulated
concentration sampling distribution with 90% confidence interval (Fig. 2E). The %shrinkage, 
an index suggestive of reliability of fit and  covariate identification,  for CLR, V1, CL12 or 
CL21 and V2 were 1.01%, 2.39%, 4.22% and 4.01% respectively, and the shrinkage for 
residual variability is 4.01%. Since these values are close to zero, individual prediction and 
individual estimates should be reliable (Table 2). 
Simulations 
Dose adjustment of maintenance or loading infusion rate in CRD patients undergoing 
CPB. The procedure of return of pump fluids has been currently instituted in the surgical 
protocol at our institution for CPB. Simulations were based upon the BART regimen with 
return of the pump contents (TXA + fluids) at the end of bypass in patients with varying 
severity of renal dysfunction.  We found that the simulated, initial plasma TXA 
concentrations at 5 min were comparable for all levels of renal impairment, but plasma TXA 
continued to rise to potentially toxic concentrations with increasing severity of renal 
dysfunction (Fig. 3A). We then adjusted the maintenance infusion rate in proportion to the 
reduction in CLR (Table 3) that would provide a predicted plasma TXA concentration of 100 
- 150 mg·L
-1
 before and during CPB (Fig. 3B). Plasma TXA concentrations were predicted to
remain at this threshold for up to 10 h post-surgery in patients with CLR below 10% of 
normal (Fig. 3B). It is further known that protein binding that may change with renal 
dysfunction [18]. The volume of distribution of TXA, however, is expected to remain 
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unchanged since TXA exhibits minimal protein binding [19]. Hence, changing the loading 
infusion rate would strongly affected the Cmax during Phase I but not the steady-state 
concentration. This was confirmed when we changed the loading dose to a single, high 
intravenous loading infusion of 50 mg·kg
-1
 (200 mg·kg
-1
·h
-1
) without giving any maintenance
infusion to CRD patients. The predicted initial TXA concentrations were high, and 
concentrations falling rapidly below the suggested threshold of 100 mg·L
-1
 were observed
during and after CPB in patients with > 25% of normal renal function (Fig. 3C).  
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DISCUSSION 
We revisited the works of Sharma [5] and Wąsowicz [14] and coworkers and employed 2-
compartment model for pharmacokinetic analysis. Our model was modified/adjusted for use 
of the extracorporeal compartment (CPB pump circuit) being used during the crucial part of 
cardiac surgery (Phase III) only; the contents in the CPB circuit were not returned. We found 
that the compartmental model describes satisfactorily the pharmacokinetics of TXA, 
especially when the entire data set is used to simultaneously estimate parameters, which were 
found similar to those of Sharma and coworkers [5]. The modeling demonstrates that the 
number of samples obtained after discontinuation of infusion exerts no significant impact on 
the estimation of pharmacokinetic parameters, but their precision was improved with longer 
sampling, evidenced by the lower CV (Table 1). 
Using the combined dataset, effects of the two major covariates: body weight on volume of 
distribution and clearance, and creatinine clearance on renal clearance, were identified and 
incorporated into the population pharmacokinetic model. Although a recent study had 
confirmed that body weight can affect TXA disposition [20], creatinine clearance, in addition 
to body weight, was identified in our study as having an important impact on TXA 
pharmacokinetics. After incorporating these two covariates, both the inter-subject variability 
and OFV were significantly improved, demonstrating that the renal clearance of TXA is 
associated with both body weight and creatinine clearance, and volume of distribution is 
linearly related with body weight. Since TXA is a weak acid (pKa of 4.3) that is mostly 
unbound to plasma proteins [19], non-lipophilic (logP of 0.3) and not reabsorbed , CLR of 
TXA approximates GFR,  and it is not surprising to find CLCr as a significant covariate. A 
similar relationship has been previously described for clearance and volume of distribution of 
methotrexate, metformin and piperacillin, which are also renally cleared [21-23]. Although it 
may be argued that data of 15 patients only provided limited population information to 
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accurately estimate parameters and inter-patient variability, confidence was assured since our 
estimated %shrinkage values are small and close to zero, the individual prediction and 
individual estimates should be relatively reliable (Table 2) with respect to covariate 
identification. If the shrinkage were substantial (> 20%), then the covariate relationship 
determined in the model might be spurious, and it is harder to detect model misspecification 
visually by diagnostic plots [24]. It appears that data from all 15 individuals, albeit small, are 
representative of the patient population. 
The identification of creatinine clearance (a reasonable and commonly accepted estimation of 
GFR in renal function [25]) as a strong determinant of TXA clearance suggests that renally-
compromised patients undergoing CPB may require dose-adjustments to offset increased 
TXA accumulation. High TXA concentrations (≥100 mg·L-1) are associated with seizures in
cardiac surgical patients and thrombotic/ischemic complications documented in patients with 
CRD undergoing prostatectomy [10, 26, 27]. Moderate TXA doses (24 mg·kg
-1
) given to
patients undergoing open-heart surgery have been associated with the risk of post-operative 
seizures that doubled in-hospital mortality [28]. Although there are several recommended 
dosing regimens in patients with normal renal function [3, 4, 29-31] (see simulated profiles in 
Supplemental Fig. 1), the TXA regimen for CRD patients is still unclear. In addition, cardiac 
surgery studies assessing TXA concentrations among CRD patients undergoing cardiac 
surgery with use of CPB are scarce, with only one study that described pharmacokinetic 
model based on a limited number (four) of CRD patients [29]. 
Simulations clearly demonstrated that the BART dose, if left unchanged, would result in an 
accumulation of TXA in CPB patients with compromised renal function. According to our 
simulations based on the compartmental model, the predicted TXA concentrations would be 
3-4 times higher for CPB patients with moderate to severe CRD (≤ 25% of normal CLR), and 
4-fold higher for dialysis patients (~1% of normal CLR) compared to those with normal renal 
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function (Fig. 3A). The predicted increase in TXA concentrations for CRD patients on the 
BART infusing regimen could be lowered to the optimal concentration of ~100 mg·L
-1
 with
our recommended dosing profile (Table 3), when the maintenance infusion rate was reduced 
in direct proportion to the %decrease in GFR or CLR (Fig. 3B).  The model further predicted 
that the prolongation of t1/2 is highly correlated to the reduction in CLR (Fig. 3C). 
There has been one other dosing regimen recommended for patients with CRD. This was 
devised by Fiechtner and coworkers [29], who proposed a 5.4 mg·kg
-1
 loading dose followed
by a 5 mg·h
-1
·kg
-1
 maintenance infusion rate, with 0.5 mg in the CPB circuit during CPB to
target TXA concentrations at ~20 mg·L
-1
 for patients with normal renal function. In patients
with renal insufficiency, the recommendation was to reduce the maintenance infusion rate to 
25%, 50% and 75% of baseline for serum creatinine concentrations above 6, 3.3-6.6 and 1.6-
3.3 mg·dL
-1
 respectively [29, 32]. Based on our simulations, however, these
recommendations generally yielded TXA concentrations (~30 mg·L
-1
)
 
during CPB that are
higher than the proposed 20 mg·L
-1
 (Fig. 4A).  For Scr above 6, 3.3-6.6 and 1.6-3.3 mg·dL
-1
,
the Cockcroft and Gault equation [33] was used to calculate corresponding CLCr. Based on 
the altered CLCr, our recommendation (matching %CLR; see Table 4) was arrived. Our 
recommendations for CRD patients predicted TXA concentrations (25 mg·L
-1
) that are only
slightly above the suggested threshold (20 mg·L
-1
) (Fig. 4A), and Fiechtner’s infusion rates
are 4.9- to 2.4-fold higher than those recommended on the basis of the simulations in this 
paper (Table 4). For this scenario, the outcome is not serious since the predicted TXA 
concentrations according to both methods remained below 100 mg·L
-1
. However, when we
examined the BART dosing regimen (higher dose) on patients with renal failure, with Scr 
varying as those described for Fiechtner and coworkers [29], the TXA concentrations 
predicted based on our recommendations hovered around 150 mg·L
-1
, close to the target
value of 100 mg·L
-1
, whereas those for Fiechtner et al.’s model [29] could be elevated as high
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as 300 mg·L
-1
 (Fig. 4B).  In both cases, the infusion rates for Fiechtner et al. are 4.9- to 2.4-
fold as much as ours. The key implication of this work suggests that reducing the 
maintenance infusion rate according to %CLR and not the loading dose for CRD patients 
(Tables 3 and 4) in order to maintain TXA at optimal threshold concentrations. 
In summary, we showed that the 2-compartment model is robust for estimation of TXA 
pharmacokinetic parameters regardless of the number of samples obtained after 
discontinuation of the infusion [5]. We identified two covariates, body weight and creatinine 
clearance, which affect TXA disposition in cardiac surgical patients operated with use of 
CPB. Additionally our findings illustrated that simulation methodologies have great potential 
benefits to patients with impaired kidney function given that TXA is renally filtered, and the 
technique provides for insight into dosage adjustments that should result in more precise 
targeting of desired exposure to TXA [34]. Our simulation study has been based on computer 
modeling and simulations, and proof of the principle needs to be verified clinically to show 
that our recommendations towards TXA regimen for CRD patients undergoing CPB are 
sound. 
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Appendix A 
 The BART regimen [3]  was separated into 5 time phases (see figure above), with a 
15-min for loading infusion (Phase I) and followed by maintenance infusion (about 10 
h).  For the regimen of Wąsowicz [14] or Sharma and coworkers [5], the maintenance 
infusion period was dramatically reduced to ~3.5 h, whereas the sampling times for 
the study of Wąsowicz and coworkers [14] during Phase V (washout) was about 2 h, 
and that for Sharma and colleagues [5] was 10 h. 
Loading infusion, 120 mg · kg-1 · h-1
Maintenance infusion 16 mg · kg-1 · h-1
Phase I:  15 min, loading infusion
Phase II: ~ 1 – 1.5 h chest opening 
Phase IV: 0.5 h, chest closure
Phase V: washout
Extracorporeal circuit (2 L) containing 2 mg·kg-1 bolus for perfusion at 5 L· min-1
–
Phase III: ~ 1.8 h, CPB
Phase I 
15 min 10 h
Phase I  ~3.5 h
Phase
II
Phase I  ~
BART regimen3
Sharma and coworkers5
IV
ase I 
 i 10 h
ase I .  h
III
ase I 3.5 h
Regimen used by Wąsowicz
and coworkers14
Regimen used by 
I
Phase V
2 h
Maintenance infusion
Phase Phase
Phase
II IVIII I
Phase Phase Phase V
10 h
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Appendix B 
 
For the protocol that did not return fluids in extracorporeal compartment (CPB pump circuit) 
back to central compartment, the rate equations are: 
 11 R 12 3 1 21 2 3 3
dC
V  = - (CL + CL + Q ) C CL C Q C
dt
     (B1)          
2
2 12 1 21 2
dC
V  = CL C CL C
dt
   (B2) 
3
3 3 1 3
dC
V  = Q (C C )
dt
     (B3) 
CLR (or k10V1) is the renal clearance; CL12 (or k12V1) = CL21 (or k21V2) are inter-
compartmental clearances from central to peripheral compartments and from peripheral to 
central compartments, respectively; Q3 is the inter-compartmental flow between central and 
extracorporeal  compartments; V1, V2 and V3 are the volume of central, peripheral and 
extracorporeal compartments, respectively, and C1, C2 and C3 are the corresponding 
concentrations. For both ADAPT5® and NONMEM®, time-dependent indicators were set to 
indicate the two periods: the non-CPB period (Phases I, II, IV, and V) and CPB period (Phase 
III).   
The third compartment was turned on with indicators specifying the time period, as follows:   
If (OCC.EQ.0), then Q3 = 5 L·min
-1
(B4)
Else Q3 = 0 L·min
-1
        End if  
where OCC stands for occasion, the indicator for different periods. 
To accommodate return of extracorporeal fluid content to the central compartment, the amount, V3C3, 
is added to that in the central compartment, and the new V2 is V2+V3, at the end of CPB. 
Central Compartment
C1, V1
Peripheral
Compartment
C2, V2
LD or Infusion ClR
Q3
Extracorporeal
Compartment
C3, V3
Cl21
connected during 
Phase III -CPB
Cl12
CL21 (or k21V2)
CL12 (or k12V1)
CLR (or k10V1)
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Table 1.  Parameter estimates for CLR, CL12 or CL21, and V1 with ADAPT5® from data of 
Wąsowicz and Sharma and colleagues [5, 14]. 
Subject
a,b
 
CLR±CV
c
(L·min
-1
) 
V1±CV 
(L) 
CL12 or CL21±CV 
(L·min
-1
) 
V2±CV 
(L) 
1 0.0805±0.116 12.7±0.108 0.0742±0.546 10.4±0.306 
2 0.114±0.120 14.4±0.139 0.188±0.738 6.44±0.371 
3 0.126±0.179 15.6±0.113 0.0924±0.584 15.1±0.397 
4 0.0826±0.128 12.3±0.125 0.0784±0.673 9.31±0.329 
5 0.11±0.129 17.0±0.130 0.215±0.601 6.79±0.301 
6 0.198±0.132 18.1±0.132 0.217±0.608 10±0.323 
7 0.121±0.128 15.1±0.134 0.151±0.703 8.61±0.329 
8 0.0833±0.138 12.2±0.139 0.16±0.667 4.76±0.320 
9 0.165±0.117 17.4±0.140 0.246±0.708 7.63±0.354 
10 0.0896±0.122 11.3±0.144 0.151±0.744 4.97±0.367 
Mean ±SEM 
 (n=10) 
0.117±0.386 14.6±2.43 0.157±0.0607 8.4±3.05 
12 0.077±0.080 11.6±0.090 0.0343±0.31 11.9±0.221 
14 0.266±0.073 25.8±0.011 0.249±0.398 14.3±0.227 
15 0.151±0.072 15.1±0.099 0.0819±0.341 14.1±0.201 
16 0.07±0.072 12.8±0.010 0.0973±0.473 7.77±0.241 
17 0.151±0.069 16.6±0.139 0.295±0.594 4.69±0.283 
Mean ±SEM 
 (n=5) 
0.143±0.0789 16.4±5.59 0.151±0.114 10.6±4.2 
P value
d
 0.768 0.768 1.000 0.440 
Mean ±SEM 
 (n=15) 
0.126±0.0538 15.2±3.67 0.155±0.0779 9.12±3.49 
a
 Subjects 1-10 were from Wąsowicz and coworkers [14]; subjects 12,14 to 17 were from Sharma and colleagues 
[5]. 
b
The estimated variance parameters are SDinter = 0.00169 and SDslope = 0.302 for the first 10 subjects, and SDinter 
= 0.00525 and SDslope = 0.35 for the other 5 subjects. 
c
 CV (= standard deviation of parameter estimate/ parameter estimate) was much lower for the fit to data of 
Sharma and coworkers [5]   
d
 Mann-Whitney U test was used to compare parameters of first 10 patients (2 samples obtained after TXA 
infusion stoppage) against those for the other 5 patients (6-8 samples obtained after TXA infusion stoppage). 
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Table 2.  NONMEM results of covariate model building steps to arrive at Model I 
Model Parameter 
Covariate 
Effect 
Estimate 
± %RSE
a
 
Between 
Subject 
Variability 
%BSV± %RSE 
[%Shrinkage]b 
Residual 
Variability 
± %RSE 
[%Shrinkage]c 
Total 
Variability 
of Model
d
 
Minimal 
OFV
e
A 
CLR (L·min
-1) NA 
0.118 
±20.1% 
60.3±12.1 
[2.20] 
0.322± 7.15 
[4.76] 
1.29 591 
V1 (L) NA 
16.1 
±7.15% 
41.5± 13.3 
[2.36] 
CL12  and 
CL21 (L·min
-
1) 
NA 
0.0839 
±53.8% 
105.8±13.2 
[22.1] 
V2 (L) NA
 13.1 
±7.8% 
3.2±12.6 
[25.9] 
B 
CLR (L·min
-1) (BW/ BW )0.75
0.122 
±22.3% 
46.9±19.7 
[3.36] 
0.301± 9.55 
[4.71] 
1.06 588 
V1 (L) (BW/ BW )
17.5 
±8.4% 
26.9± 19.9 
[2.01] 
CL12  and 
CL21 (L·min
-
1) 
(BW/ BW )0.75
0.0820 
±129.9% 
89.2±18.1 
[18.9] 
V2 (L) (BW/ BW )
6.6 
±121% 
19.3±19.5 
[10.3] 
C 
CLR (L·h
-1)
(BW/ BW )ϴ1
0.131 
±11.2% 
33.2±22.5 
[1.15] 
0.237±3.81 
[4.40] 
1.22 582 
ϴ1
f 3.28 
±9.61% 
N.A. 
V1 (L) (BW/ BW )
20 
±10.6% 
29.8±19.9 
[2.63] 
CL12  and 
CL21 (L·h
-1)
(BW/ BW ) ϴ2 
0.0863 
±1.04% 
3.20±20.0 
[3.92] 
ϴ2
f 0.325 
±3.66% 
N.A. 
V2 (L) (BW/ BW )
12.6 
±39.8% 
114±22.3 
[5.49] 
D 
CLR (L·h
-1)
(BW/ BW )ϴ1
0.124 
±11.3% 
43.2±17.7 
[1.49] 
0.332±5.15 
[4.41] 
0.726 552 
ϴ1 
1.27 
±21.0% 
N.A. 
V1 (L) (BW/ BW )
12.8 
±8.16% 
26.1±17.1 
[2.08] 
CL12  and 
CL21 (L·h
-1)
(BW/ BW ) ϴ2
 
0.0968 
±15.2% 
N.A. 
ϴ2 
1.12 
±1.40% 
52.1±18.4 
[3.49] 
V2 (L) N.A.
8.86 
±1.08% 
3.33±17.8 
[2.02] 
E 
CLR (L·h
-1)
(CLCr/ crCL )
ϴ
1
0.134 
±13.4% 
41.7±10.8 
[1.55] 
0.338±3.67% 
[4.41] 
0.579 573 
ϴ1 
0.429 
±25.6% 
N.A. 
V1 (L) N.A. 
13.2 
±10.4% 
31.9±12.0 
[2.05] 
CL12  and 
CL21 (L·h
-1)
(CLCr/ crCL )
ϴ
2
0.0650 
±4.59% 
12.2±12.7 
[3.55] 
ϴ2 
1.89 
±2.20% 
N.A. 
V2 (L) N.A. 
5.86 
±10.6% 
21.2±13.9 
[4.95] 
F CLR (L·h
-1) Exp(ϴ1*(CLCr/ 0.071 46.3±18.4 0.323±3.37 0.839 582 
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a SEM/parameter estimate 
b %Shrinkage for between- or inter-subject variability, if substantial (>30%), is suggestive that covariates might be falsely 
introduced or the covariate relationship is spurious; 
  if %Shrinkage  is ~0,   then estimated parameter and incorporated covariate relationship are relatively more reliable. 
c Residual variability is the remaining, random variability, after adjustment for inter-subject variability (and/or inter-occasion 
variability).
d Sum of between- or inter-subject variability for each of the parameters, or [∑η2(CLR+V1+Q2+V2)]
1/2, where η denotes BSV,
or variability of parameter estimate
e Objective function value, parameter that indicates improved model fit; the lower the value, the better the fit 
f Fitted exponent, and not the assigned 0.75 exponent, for allometric scaling
crCL )) 
. 
±27.2% [3.19] [6.38] 
ϴ1 
0.558 
±20.4% 
N.A. 
V1 (L) N.A. 
14.4 
±8.16% 
35.5±10.3 
[12.6] 
CL12  and 
CL21 (L·h
-1) Exp(ϴ2*(CLCr/
crCL )) 
0.0825 
±23.8% 
21.3±18.0 
[28.9] 
ϴ2 
1.02 
±8.41% 
N.A. 
V2 (L) N.A. 
7.54 
±18.6% 
56.4±18.4 
[23.7] 
G 
CLR (L·h
-1)
(CLCr/ crCL )
ϴ
1
0.137 
±13.4% 
43.2±17.7 
[1.06] 
0.332±5.15 
[4.41] 
0.726 562 
ϴ1 
1.37 
±6.1% 
N.A. 
V1 (L) (BW/ BW )
19 
±8.47% 
26.1±71.0 
[1.69] 
CL12  and 
CL21 (L·h
-1)
(BW/ BW ) ϴ2
0.0767 
±15.3% 
52.1±28.0 
[3.49] 
ϴ2 
1.22 
±26.1% 
N.A. 
V2 (L) N.A. 
7.6 
±1.08% 
3.3±17.8 
[3.48] 
H 
CLR (L·h
-1)
(CLCr/ crCL )
ϴ
1
0.120 
±16.8% 
45.5±11.6 
[1.75] 
0.314±3.5 
[4.1] 
0.937 546 
ϴ1 
0.86 
±13.6% 
N.A. 
V1 (L) (BW/ BW )
14.9 
±6.81% 
3.1±12.0 
[2.04] 
CL12  and 
CL21 (L·h
-1) (CLCr/ crCL )
ϴ
2
0.0867 
±20.0% 
80.9±12.7 
[3.38] 
ϴ2 
1.06 
±16.4% 
N.A. 
V2 (L) N.A. 
12.3 
±8.54% 
12.8±12.7 
[3.75] 
I 
CLR (L·h
-1)
(BW/ BW )ϴ1*
(CLcr/ crCL )
 ϴ
2
. 
0.116 
±16.7% 
38.0±17.3 
[1.01] 
0.332±3.73 
[4.01] 
0.478 517 
ϴ1 
0.0445 
±15.3% 
N.A. 
ϴ2 
1.21 
±16.9% 
N.A. 
V1 (L) (BW/ BW )
17.3 
±5.37% 
21.4±19.6 
[2.39] 
CL12  and 
CL21 (L·h
-1)
(CLcr/ crCL )
 ϴ
3
0.0110 
±13.3% 
19.4±17.6 
[4.22] 
ϴ3 
-0.607 
±11.5% 
N.A. 
V2 (L) N.A. 
9.5 
±10.6% 
1.5±19.4 
[4.01] 
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Table 3. Reduction of maintenance infusion rate (MD) for conditions of reduced CLR 
%GFR or %CLR 
100% 75% 50% 25% 10% 5% 1% 
CLR
a
(L·min
-1
) 
0.116 0.0868 0.0581 0.0287 0.119 0.0056 0.0014 
Maintenance 
Infusion (MD) Rate  
(mg·h
-1
·kg
-1
) 
16 12
a
6
a
5
a
1.6
a
0.8
a
0.16
a
a
Pharmacokinetic parameters were presented in terms of a standard individual with body weight of 70 kg.
   b
Estimated as %GFR multiplied to the starting maintenance dose of 16 mg·h
-1
·kg
-1
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Table 4 Recommended dosing regimen by Fiechtner
 
and our study to maintain plasma TXA 
concentrations of 20 mg·L
-1
.
Fiechtner and coworkers recommended reduction in maintenance infusion rate (MD) based 
on Scr [29], whereas ours was based on upon converting Scr to CLCr (or CLR) using the 
Cockcroft-Gault equation [33]; our recommended change in MD equaled %CLR x normal 
MD.  Fiechtner and colleagues used a loading dose of 5.4 mg.kg
-1
, and MD 5 mg.kg
-1
.h
-1 
for
patients with normal renal function. The MD of Fiechtner and coworkers [29] were 2.4- to 
4.9-fold our recommendations (see table below):  
Scr 
(mg·dL
-1
) 
%Reduction in 
MD 
suggested by 
Fiechtner and 
coworkers
a
 
CLCr   
(%CL•min-1) b 
Estimated Based on Scr 
%CLCr/GFR
c
  %Reduction in CLR
=%Reduction in MD
d
 
Ratio of Maintenance 
Infusion (MD) Rates 
(Fiechtner/ 
our recommendation) Female Male 
>6.6 25 0-13.8 0-11.7 5.1 4.9 
3.3-6.6 50 13.8-27.5 11.7-23.4 15.4 3.25 
1.6-3.3 75 27.5-56.7 23.4-48.2 31.4 2.39 
a
 Suggested by Fiechtner and coworkers
 
[29] for the given Scr 
b 
CLCr values were estimated with the Cockcroft-Gault equation [33], assuming BW = 86 kg, age= 64 for both sexes.  
c
CLCr  / GFR (110 mL·min
-1
 for females and 140 mL·min
-1
 for male), and values were averaged
d 
We recommend maintenance infusion to match %CLR of normal.   
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Fig.1  Fitted (solid lines) and observed (solid symbols) TXA concentrations versus time 
plots for (A) shorter and (B) longer sampling time. For these data sets, pump fluids 
containing TXA were not returned to patients at the end of CPB. Each patient is 
marked by a different color, and the grey shaded area represents the CPB period. The 
dotted black line demarcates the suggested concentration (100 mg·L
-1
) for 100% anti-
fibrinolytic effect of TXA. Three patients show TXA concentrations consistently 
lower than the suggested threshold, indicated by the black arrows.   
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Fig. 2 Plots showing improvement of model predictability based on observed vs. individual and 
population predicted concentration profiles from (A) the basic (a) to the final (b) model 
[red line is regression line and the blue line is the line of identity], and diagnostic plots (B)-
(F) for the final model, Model I: (B) and (C) show the distribution of conditional weighted 
residuals (CWRES) vs. time and vs. population prediction, respectively; these data hovered 
around the y=zero line, showing goodness of fit, and (D) shows the test of normality of 
frequency vs. CWRES, with the mean=1 and variance of CWRES=0, respectively, by the 
Wilcoxon signed rank test (P = .31), Fisher’s variance test (P = .53), and the Shapiro-Wilk 
test of normality; the data show that CWRES follows a normal distribution (P = .71); (E) the 
visual predictive check, plot was generated by NONMEM $simulation based on the final 
model I, suggests that the final model has good precision relative to the variation contained in 
the raw observation. The solid and dashed red lines represent the median and 5% and 95% 
quartiles of observed data, respectively, and the semitransparent blue fields are the 
corresponding 90% confidence intervals. The solid and dashed red lines denote the median, 5% 
and 95% quartiles of observed data, respectively. 
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Fig. 3 Simulated TXA concentration vs. time profile with (A) no adjustments in the 
BART regimen to CRD patients; (B) %reduction of maintenance infusion dose 
(MD) proportionally to the %reduction in CLR of CRD patients; and (C) a single 
loading dose of 200 mg·kg
-1
·h
-1 
(50 mg·kg
-1
) in CRD patients. For these simulations, 
pump fluids containing TXA were returned to patients at the end of CPB. The 
different severity of CRD is represented by reducing renal clearance values (CLR) 
according to different percentage (75, 50, 25, 10, 5, and 1%) of normal CLR. The grey 
shaded area represents the CPB period and the dotted black lines represent the 
suggested concentration (100 mg·L
-1
) allowing 100% anti-fibrinolytic effect of TXA.  
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Fig. 4 TXA concentration vs. time profiles simulated according to the two-
compartmental model (with return of CPB contents) using Fiechtner’s 
recommendation [29] (solid line) as well as our recommendations (dashed line) 
based on reduction of the maintenance infusion dose (MD), when the serum 
creatinine concentration (Scr) was converted to %CLR according to the 
Cockcroft-Gault equation [33] for targeting 20 mg·L
-1 
(A) or 100 mg·L
-1 
(B).  For 
(B), the dosing regimen in BART trial [3] was used. See text for details. Notably, our 
recommendation provided simulated TXA concentrations closer to the 20 and 100 
mg·L
-1
 targets, compared to those of Fietchner and coworkers [29].  
